Phreesia, Inc.

NYSE:PHR Voorraadrapport

Marktkapitalisatie: US$1.3b

De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

Phreesia Beheer

Beheer criteriumcontroles 2/4

De CEO Phreesia's is Chaim Indig, benoemd in Jan2005, heeft een ambtstermijn van 19.75 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 8.27M, bestaande uit 6% salaris en 94% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 2.24% van de aandelen van het bedrijf, ter waarde $ 29.55M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 3.8 jaar en 17 jaar.

Belangrijke informatie

Chaim Indig

Algemeen directeur

US$8.3m

Totale compensatie

Percentage CEO-salaris6.0%
Dienstverband CEO19.8yrs
Eigendom CEO2.2%
Management gemiddelde ambtstermijn3.8yrs
Gemiddelde ambtstermijn bestuur17yrs

Recente managementupdates

Recent updates

Here's What Analysts Are Forecasting For Phreesia, Inc. (NYSE:PHR) After Its Second-Quarter Results

Sep 06
Here's What Analysts Are Forecasting For Phreesia, Inc. (NYSE:PHR) After Its Second-Quarter Results

Phreesia: Remain Bullish Given The Healthy Growth Outlook

Sep 05

Market Participants Recognise Phreesia, Inc.'s (NYSE:PHR) Revenues Pushing Shares 26% Higher

Jul 18
Market Participants Recognise Phreesia, Inc.'s (NYSE:PHR) Revenues Pushing Shares 26% Higher

Phreesia: Growth Remains Strong, With EBITDA Margin Set To Improve

Jun 06

The Price Is Right For Phreesia, Inc. (NYSE:PHR)

May 25
The Price Is Right For Phreesia, Inc. (NYSE:PHR)

Are Investors Undervaluing Phreesia, Inc. (NYSE:PHR) By 39%?

May 03
Are Investors Undervaluing Phreesia, Inc. (NYSE:PHR) By 39%?

At US$23.80, Is Phreesia, Inc. (NYSE:PHR) Worth Looking At Closely?

Apr 12
At US$23.80, Is Phreesia, Inc. (NYSE:PHR) Worth Looking At Closely?

Phreesia Continues To Stay Positive On The Business Growth

Apr 03

Phreesia: Healthcare Digitization Beneficiary Hampered By Valuation

Mar 01

Investors Still Waiting For A Pull Back In Phreesia, Inc. (NYSE:PHR)

Feb 16
Investors Still Waiting For A Pull Back In Phreesia, Inc. (NYSE:PHR)

Phreesia: Remain Buy Rated As The Business Pivot Towards Profitable Growth

Jan 04

Is Phreesia Finally Turning The Corner?

Dec 07

Does Phreesia (NYSE:PHR) Have A Healthy Balance Sheet?

Oct 25
Does Phreesia (NYSE:PHR) Have A Healthy Balance Sheet?

Phreesia: Share Price Dip Is A Buying Opportunity

Sep 21

Phreesia: Strong Execution Should Continue To Drive Growth

Jul 11

Phreesia, Inc.'s (NYSE:PHR) Share Price Matching Investor Opinion

May 18
Phreesia, Inc.'s (NYSE:PHR) Share Price Matching Investor Opinion

Phreesia: Strong Growth Momentum With Expanded TAM

Jan 28

Phreesia - Healthcare Ecosystem At An Attractive Valuation

Dec 13

Phreesia Q3 2023 Earnings Preview

Dec 07

Phreesia GAAP EPS of -$0.89 beats by $0.08, revenue of $67.9M beats by $2.15M

Sep 07

Phreesia: Their Time Has Passed

May 10

Opportunistic Time To Buy Phreesia's Healthcare Disruption

Dec 27

Analyse CEO-vergoeding

Hoe is Chaim Indig's beloning veranderd ten opzichte van Phreesia's winst?
DatumTotale vergoedingSalarisBedrijfswinsten
Jul 31 2024n/an/a

-US$100m

Apr 30 2024n/an/a

-US$119m

Jan 31 2024US$8mUS$495k

-US$137m

Oct 31 2023n/an/a

-US$144m

Jul 31 2023n/an/a

-US$152m

Apr 30 2023n/an/a

-US$162m

Jan 31 2023US$8mUS$515k

-US$176m

Oct 31 2022n/an/a

-US$185m

Jul 31 2022n/an/a

-US$181m

Apr 30 2022n/an/a

-US$158m

Jan 31 2022US$9mUS$515k

-US$118m

Oct 31 2021n/an/a

-US$80m

Jul 31 2021n/an/a

-US$50m

Apr 30 2021n/an/a

-US$32m

Jan 31 2021US$6mUS$419k

-US$27m

Oct 31 2020n/an/a

-US$23m

Jul 31 2020n/an/a

-US$19m

Apr 30 2020n/an/a

-US$83m

Jan 31 2020US$10mUS$346k

-US$91m

Oct 31 2019n/an/a

-US$102m

Jul 31 2019n/an/a

-US$113m

Apr 30 2019n/an/a

-US$54m

Jan 31 2019US$510kUS$300k

-US$45m

Compensatie versus markt: De totale vergoeding ($USD 8.27M ) Chaim } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 5.54M ).

Compensatie versus inkomsten: De vergoeding van Chaim is gestegen terwijl het bedrijf verliesgevend is.

CEO

Chaim Indig (44 yo)

19.8yrs

Tenure

US$8,273,307

Compensatie

Mr. Chaim Indig co-founded Phreesia, Inc. in January 2005 and serves as Chief Executive Officer and Director since January 2005. Mr. Indig has helped to revolutionize the patient check-in experience. Under...

Leiderschapsteam

NaamPositieTenureCompensatieEigendom
Chaim Indig
Co-Founder19.8yrsUS$8.27m2.24%
$ 28.8m
Evan Roberts
Co-Founder & COO19.8yrsUS$4.50m1.31%
$ 16.8m
Balaji Gandhi
Chief Financial Officer1.6yrsUS$5.91m0.17%
$ 2.2m
Allison Hoffman
General Counsel & Secretary4.2yrsUS$3.04m0.080%
$ 1.0m
David Linetsky
Senior Vice President of Life Sciences5.6yrsUS$4.47m0.37%
$ 4.7m
Yvonne Hui
VP & Principal Accounting Officerless than a yeargeen gegevensgeen gegevens
Jack Callahan
Chief Technology Officerless than a yeargeen gegevensgeen gegevens
Maureen McKinney
Vice President of Corporate Communications3.8yrsgeen gegevensgeen gegevens
Ashwin Uttamchandani
Vice President of Sales & Marketing Operationsno datageen gegevensgeen gegevens
Amy VanDuyn
Senior Vice President of Human Resources14.5yrsgeen gegevens0.21%
$ 2.7m
Hilary Hatch
Chief Clinical Officer3.5yrsgeen gegevensgeen gegevens
Melissa Mitchell
Chief Privacy Officer1.3yrsgeen gegevensgeen gegevens

3.8yrs

Gemiddelde duur

44yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van PHR wordt beschouwd als ervaren (gemiddelde ambtstermijn 3.8 jaar).

Bestuursleden

NaamPositieTenureCompensatieEigendom
Chaim Indig
Co-Founder19.8yrsUS$8.27m2.24%
$ 28.8m
Eve Kurtin
Board Observerno datageen gegevensgeen gegevens
Edward Cahill
Independent Director17yrsUS$232.46k0.072%
$ 925.9k
Michael Weintraub
Independent Chairman19.8yrsUS$384.98k0.57%
$ 7.4m
Richard Jackson
Member of Medical Advisory Boardno datageen gegevensgeen gegevens
Gillian Munson
Independent Director5.4yrsUS$257.46k0.018%
$ 226.7k
Elsa-Grace Giardina
Member of Medical Advisory Boardno datageen gegevensgeen gegevens
Mark Blais
Member of Medical Advisory Boardno datageen gegevensgeen gegevens
Michael Brodman
Member of Medical Advisory Boardno datageen gegevensgeen gegevens
Lee Schwamm
Member of Medical Advisory Boardno datageen gegevensgeen gegevens
Susan MacDonald
Member of Medical Advisory Boardno datageen gegevensgeen gegevens
Mark Smith
Independent Director6yrsUS$244.98k0.011%
$ 135.6k

17.0yrs

Gemiddelde duur

62yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van PHR zijn ervaren en ervaren (gemiddelde ambtstermijn van 17 jaar).